Table 3.
Glutamate receptor expression and effective antagonists in different cancer cell lines.
| Cancer type | Cell line | GluR genes detected | Glu antagonists with growth inhibitory effect | Refs |
|---|---|---|---|---|
| Glioma | U87-MG, U343, C6 | mGluR1-8, NR2-3, GluR2-7, KA1-2 | Memantine, MK801 | 33, 91 |
| Neuroblastoma | SK-N-AS | mGluR2-8, NR1-3, GluR2-4, 6-7, KA1-2 | Dizocilpine, GYKI 52466 | 91 |
|
Rhabdomyosarcoma & Medulloblastoma |
TE671 | mGluR2-4, 6-8, NR1-3, KA1-2, GluR2, 4, 6, 7 | Dizocilpine, GYKI 52466 | 91 |
| Astrocytoma | MOGGCCM | mGluR1-8, NR1-3, KA1-2, GluR1-4; GluR6-7 | Dizocilpine, GYKI 52466 | 91 |
| Lung carcinoma | SK-LU-1 | mGluR1-2, 4-8, NR1-3, KA1-2, GluR1-2, 4, 6 | N.D. | 91 |
| Colon adenocarcinoma | HT29, LS180 | mGluR1-8, NR1-3, KA1-2, GluR1-2, 4, 6-7 | Dizocilpine, GYKI 52466 | 91 |
| T-cell leukemia | Jurkat E6.1 | mGluR1-7, NR2-3, KA1-2, GluR2-4, 6-7 | N.D. | 91 |
| Multiple myeloma | RPMI 8226 | mGluR2-7, NR1-2, KA1-2, GluR4, 6 | N.D. | 91 |
| Breast carcinoma | T47D | mGluR1-7, NR1-3, KA1-2, GluR2, 4-7 | Dizocilpine, BAY36-7620, riluzole, GYKI 52466 | 91, 133 |
| Thyroid carcinoma | FTC 238 | mGluR2, 4, 7, NR1-3, KA1-2, GluR2-4, 6-7 | Dizocilpine, GYKI 52466 | 91 |
| Prostate carcinoma | PC-3, LNCaP, DU145, VCaP, 22RV1, E006AA, MDA-PCa2B, | mGluR1a, mGluR1-8, NR1-3 | Riluzole, BAY36-7620 | 32, 61,71, 91 |
| Melanoma | C8161, UACC903, HT144, SKMEL2 | mGluR1 | Riluzole, BAY36-7620 | 130 |